Alternative RNA splicing and drug target identification

IDrugs

Volumn 8, Issue 9, 2005, Pages 725-729

  Mangasarian, Aram ^a  

^a ExonHit Therapeutics SA   (France)

Author keywords

Alternative splicing; DNA chip; Drug discovery; Expression profiling; Microarray; Pharmacology

Indexed keywords

CELL NUCLEUS RECEPTOR; CLOZAPINE; DOPAMINE 2 RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; G PROTEIN COUPLED RECEPTOR; GENE PRODUCT; GENOMIC DNA; GROWTH FACTOR RECEPTOR; ION CHANNEL; MESSENGER RNA; RACLOPRIDE;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; CANCER GENETICS; CARCINOGENESIS; DNA MICROARRAY; DNA SEQUENCE; DRUG RESEARCH; DRUG TARGETING; EXON; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC CODE; GENETIC DISORDER; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN GENOME; NONHUMAN; POINT MUTATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; VIRUS INFECTION;

ALTERNATIVE SPLICING; ANIMALS; APOPTOSIS; DRUG DESIGN; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 24644517091     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Faustino NA, Cooper TA: Pre-mRNA splicing and human disease. Genes Dev (2003) 17(4):419-437.
2. Dechering KJ: The transcriptome's drugable frequenters. Drug Disc Today (2005) 10(12):857-864.
3. Fehlbaum P, Guihal C, Bracco L, Cochet O: A microarray configuration to quantity expression levels and relative abundance of splice variants. Nucleic Acids Res (2005) 33(5):e47
4. Black DL: Protein diversity from alternative splicing: A challenge for bioinformatics and post-genome biology. Cell (2000) 103(3):367-370.
5. Harrison PM, Kumar A, Lang N, Snyder M, Gerstein M: A question of size: The eukaryotic proteome and the problems in defining it. Nucleic Acids Res (2002) 30(5):1083-1090.
6. Resch A, Xing Y, Modrek B, Gorlick M, Riley R, Lee C: Assessing the impact of alternative splicing on domain interactions in the human proteome. J Proteome Res (2004) 3(1):76-83.